TABLE OF CONTENTS
|  |  |  | | Volume 37, Issue 39 |  | In this issue Article Also new AOP | |  |  |  | Article |  |  | Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4–miR-18a pathway in cervical cancer Peixin Dong, Ying Xiong, Jiehai Yu, Lin Chen, Tang Tao et al. Oncogene 2018 37 :5257 - 5268; May 31, 2018; 10.1038/s41388-018-0347-4 Abstract | Full Text |  |  |  |  | Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option Hauke Stamm, Felix Klingler, Eva-Maria Grossjohann, Jana Muschhammer, Eik Vettorazzi et al. Oncogene 2018 37 :5269 - 5280; May 31, 2018; 10.1038/s41388-018-0288-y Abstract | Full Text |  |  |  |  | TRPS1 regulates oestrogen receptor binding and histone acetylation at enhancers A. A. Serandour, H. Mohammed, A. Miremadi, K. W. Mulder & J. S. Carroll Oncogene 2018 37 :5281 - 5291; June 12, 2018; 10.1038/s41388-018-0312-2 Abstract | Full Text |  |  |  |  | Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide Lu Lu, Jiali Dong, Lili Wang, Qing Xia, Dan Zhang et al. Oncogene 2018 37 :5292 - 5304; May 31, 2018; 10.1038/s41388-018-0340-y Abstract | Full Text |  |  |  |  | Protective effect of stromal Dickkopf-3 in prostate cancer: opposing roles for TGFBI and ECM-1 Zainab Al Shareef, Hoda Kardooni, Virginia Murillo-Garzón, Giacomo Domenici, Emmanouil Stylianakis et al. Oncogene 2018 37 :5305 - 5324; June 01, 2018; 10.1038/s41388-018-0294-0 Abstract | Full Text |  |  |  |  | BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis Ulrike Heinicke, Tinka Haydn, Sarah Kehr, Meike Vogler & Simone Fulda Oncogene 2018 37 :5325 - 5339; June 01, 2018; 10.1038/s41388-018-0212-5 Abstract | Full Text |  |  |  |  | FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial–mesenchymal transition, and metastasis in FGFR1-amplified lung cancer Kaixuan Wang, Wenxiang Ji, Yongfeng Yu, Ziming Li, Xiaomin Niu et al. Oncogene 2018 37 :5340 - 5354; June 01, 2018; 10.1038/s41388-018-0311-3 Abstract | Full Text |  |  |  |  | SYT7 acts as a driver of hepatic metastasis formation of gastric cancer cells Mitsuro Kanda, Haruyoshi Tanaka, Dai Shimizu, Takashi Miwa, Shinichi Umeda et al. Oncogene 2018 37 :5355 - 5366; June 01, 2018; 10.1038/s41388-018-0335-8 Abstract | Full Text |  |  |  |  |  |  |  | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com |  |  |  |  |  | |  | | Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Oncogene. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. Nature is part of Springer Nature. © 2018 Springer Nature Limited. All rights reserved. |  | | | |
No comments:
Post a Comment